By Nigel Somerville, the Deputy Sheriff of AIM | Saturday 5 March 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
AIM-listed and surely sort of cash Advanced Oncotherapy (AVO) announced yesterday morning that Prof Stephen Myers, executive director and the chairman of ADAM – Advanced’s development team in Geneva – had bought a total of 140,000 shares. At 27.64p (on average) that is £38,700 worth of stock. It sounds quite impressive, but this is certainly not a situation where it is advisable to follow director buying. In fact, I take the opposite view: the shares are a sell.
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Time left: 07:37:53